Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04704024 · ClinicalTrials.gov registry record · Phase 3
Reducing Vertical Transmission of Hepatitis B in Africa
A Phase 3 study of Hepatitis B Infection, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- Phase 3
- Development phase
- 450
- Enrollment target
- 1
- Study location
NCT04704024: Active Phase 3 study of Hepatitis B Infection, sponsored by University of Alabama at Birmingham.
NCT04704024 is a Phase 3 study of Hepatitis B Infection that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 450 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04704024, a Phase 3 study of Hepatitis B Infection, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 450 participants
- Enrollment target
- 1
- Study location
Study Summary
Hepatitis B virus is an infection that can be easily transmitted from women to newborns at the time of delivery. Our objective is to identify novel options that are effective and safe in preventing perinatal transmission of hepatitis B in Africa. The REVERT-B study (Reducing Vertical Transmission of Hepatitis B in Africa) is a clinical trial designed to test a new strategy of using antiviral medication in high-risk pregnant women and newborns to reduce the risk of hepatitis B transmission. The study will measure efficacy, safety, tolerability and adherence to medication.
Primary Outcome
The proportion of infants with Hepatitis B surface antigen positivity (SAg+)
Conditions Studied
Interventions
- DRUG Tenofovir Disoproxil Fumarate
- DRUG Lamivudine Oral Solution
Study Locations (1)
Alabama
- University of Alabama at Birmingham - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 450 participants |
| Start Date | 2021-09-03 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
What the registry record for NCT04704024 still lists
NCT04704024 is an interventional study that assigns participants to a tested intervention. The registered 450 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (42% lower).
The record links to 1 condition, with Hepatitis B Infection appearing as the primary indexed condition, and to 2 interventions - of which Tenofovir Disoproxil Fumarate is the first listed.
NCT04704024 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT04704024 about?
NCT04704024 is a clinical study titled "Reducing Vertical Transmission of Hepatitis B in Africa". Hepatitis B virus is an infection that can be easily transmitted from women to newborns at the time of delivery. Our objective is to identify novel options that are effective and safe in preventing perinatal transmission of hepatitis B in Africa. The REVERT-B study (Reducing Vertical Transmission of...
What is the current status of trial NCT04704024?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 450 participants. The study started on 2021-09-03. Estimated completion is 2026-12-31.
What conditions does trial NCT04704024 study?
This clinical trial studies the following conditions: Hepatitis B Infection.
What interventions are being tested in trial NCT04704024?
The interventions under investigation include: Tenofovir Disoproxil Fumarate (DRUG), Lamivudine Oral Solution (DRUG).
Who is sponsoring clinical trial NCT04704024?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04704024 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis B Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04704024's enrollment target sits among peer trials
450 838th of 2000 higher than 1,137 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Social-environmental, Psychosocial, Behavioral, Clinical and Biological Drivers of Disparities in Liver Disease Progression Among Korean American With Chronic Hepatitis B Infection
ACTIVE NOT RECRUITING
-
Effect of Entecavir in Blacks/African Americans and Hispanics With Chronic Hepatitis B Virus (HBV) Infection
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00515060 · 450 participants
Psychophysical Studies of Cancer Therapy Pain
- NCT01257269 · 450 participants
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
- NCT03047161 · 450 participants
Electrophysiology of Fetal Arrhythmia
- NCT03269630 · 450 participants
New Orleans Pulmonary Hypertension Biobank
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI